Thomas E. Pennington

1.9k citations
42 papers · 287 · h-index 9

Impact in

  • Oncology
    • Cutaneous Melanoma Detection and Management
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
  • Nephrology
    • Parathyroid Disorders and Treatments

Papers in

  • Oncology 31
    • Cutaneous Melanoma Detection and Management 29
    • CAR-T cell therapy research 12
    • Cancer Immunotherapy and Biomarkers 9
  • Molecular Biology 12
    • Melanoma and MAPK Pathways 12
Co-authors
Craig A. Hutton (1 shared paper)Alexander M. Menzies (22 shared papers)Georgina V. Long (22 shared papers)Richard A. Scolyer (23 shared papers)Andrew J. Spillane (23 shared papers)Robyn P.M. Saw (26 shared papers)Kerwin F. Shannon (18 shared papers)Maria Gonzalez (10 shared papers)
Journals
Journal of Clinical Oncology (9 papers)Annals of Surgical Oncology (6 papers)Annals of Oncology (5 papers)European Journal of Cancer (3 papers)European Journal of Surgical Oncology (2 papers)
Partner nations
AustraliaNetherlandsUnited Kingdom

In The Last Decade

Thomas E. Pennington

35 papers receiving 284 citations

Peers

Thomas E. Pennington
Comparison fields: 5 of 46
  • Oncology 174
  • Nephrology 22
  • Immunology 59
  • Organic Chemistry 43
  • Biophysics 6
Replace Feifei Gu with:
Feifei Gu China
Monique D. Appelman Netherlands
Ping Ai China
Cristina Valero Spain
Huixiong Xu China
Junqing Gan China
Bojan Stojanović Serbia
Qinglong Kong China
Chengfeng Wang China
Thomas E. Pennington relative to Feifei Gu China Feifei Gu's profile →
Citations per field
00.5×2×4×5.4×
Feifei Gu · 1×
Citations per year

Countries citing papers authored by Thomas E. Pennington

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Pennington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Pennington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Pennington more than expected).

Fields of papers citing papers by Thomas E. Pennington

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Pennington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Pennington. The network helps show where Thomas E. Pennington may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas E. Pennington, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas E. Pennington Line = papers co-authored together Thomas E. Pennington links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Deprotection of pinacolyl boronate esters by transesterification with polystyrene–boronic acid
Tetrahedron Letters ·Thomas E. Pennington, Cynantya Kardiman, Craig A. Hutton
200453
2
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Journal of Clinical Oncology ·Christian U. Blank, Irene L. M. Reijers, Thomas E. Pennington, Judith M. Versluis, Robyn P.M. Saw, Elisa A. Rozeman, Ellen Kapiteijn, Astrid Aplonia Maria Van Der Veldt, Karijn P.M. Suijkerbuijk, Geke A.P. Hospers, W. Martin C. Klop, Karolina Sikorska, Jos A. van der Hage, Dirk J. Grünhagen, Andrew J. Spillane, Robert V. Rawson, Bart A. van de Wiel, Alexander M. Menzies, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long
202040
3
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
Journal of Clinical Oncology ·Minke W. Lucas, J. Lijnsvelt, Saskia Pulleman, Richard A. Scolyer, Alexander M. Menzies, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Kerwin F. Shannon, Thomas E. Pennington, Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, Astrid Aplonia Maria Van Der Veldt, Matteo S. Carlino, Shahneen Sandhu, Maria Gonzalez, Charlotte L. Zuur, W. Martin C. Klop, Georgina V. Long, Christian U. Blank
202235
4
Oxyphil Cell Parathyroid Adenomas Causing Primary Hyperparathyroidism: a Clinico-Pathological Correlation
Endocrine Pathology ·Pamela Howson, Schelto Kruijff, Ahmad Aniss, Thomas E. Pennington, Anthony J. Gill, Tristan Dodds, Leigh Delbridge, Stan B. Sidhu, Mark Sywak
201522
5
NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.
Journal of Clinical Oncology ·Georgina V. Long, Matteo S. Carlino, George Au‐Yeung, Andrew J. Spillane, Kerwin F. Shannon, David Gyorki, Julie R. Howle, Sydney Ch’ng, Maria Gonzalez, Robyn P.M. Saw, Thomas E. Pennington, Serigne Lo, Richard A. Scolyer, Alexander M. Menzies
202221
6
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
Nature Medicine ·Georgina V. Long, Matteo S. Carlino, George Au‐Yeung, (unknown), Kerwin F. Shannon, David Gyorki, Edward Hsiao, Rony Kapoor, Jake Thompson, Iris Batula, Julie R. Howle, Sydney Ch’ng, Maria Gonzalez, Robyn P.M. Saw, Thomas E. Pennington, Serigne Lo, Richard A. Scolyer, Alexander M. Menzies
202418
7
793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma
Annals of Oncology ·Georgina V. Long, Andrew J. Spillane, Thomas E. Pennington, Kerwin F. Shannon, Jonathan R. Stretch, Maria Gonzalez, R.P.M. Saw, Serigne Lo, Richard A. Scolyer, Alexander M. Menzies
202211
8
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Journal of Clinical Oncology ·Christian U. Blank, Irene L. M. Reijers, Robyn P.M. Saw, Judith M. Versluis, Thomas E. Pennington, Ellen Kapiteijn, Astrid Aplonia Maria Van Der Veldt, Karijn P.M. Suijkerbuijk, Geke A.P. Hospers, Winan J. van Houdt, W. Martin C. Klop, Karolina Sikorska, Jos A. van der Hage, Dirk J. Grünhagen, Andrew J. Colebatch, Andrew J. Spillane, Bart A. van de Wiel, Alexander M. Menzies, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long
202210
9
Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes
European Journal of Cancer ·Mary‐Ann El Sharouni, Richard A. Scolyer, Carla H. van Gils, Sydney Ch’ng, Omgo E. Nieweg, Thomas E. Pennington, Robyn P.M. Saw, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, Arjen J. Witkamp, V. Sigurdsson, John F. Thompson, P. J. van Diest, Serigne Lo
20228
10
LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study
Annals of Oncology ·Christian U. Blank, Irene L. M. Reijers, Judith M. Versluis, Alexander M. Menzies, Petros Dimitriadis, Michel W.J.M. Wouters, R.P.M. Saw, W. Martin C. Klop, Thomas E. Pennington, Linda J.W. Bosch, Sten Cornelissen, Lindsay G. Grijpink-Ongering, M.J.C. Gregorio, Marta López‐Yurda, Robert V. Rawson, Andrew J. Spillane, Bart A. van de Wiel, Richard A. Scolyer, Alexander C. J. van Akkooi, Georgina V. Long
20218
11
Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
Annals of Surgical Oncology ·Andrew T. Li, Kavita T. Vakharia, Serigne Lo, Alexander H. R. Varey, Matteo S. Carlino, Robyn P.M. Saw, Kerwin F. Shannon, Julie R. Howle, Thomas E. Pennington, Jonathan R. Stretch, Omgo E. Nieweg, Andrew J. Spillane, Georgina V. Long, Alexander M. Menzies, Richard A. Scolyer, John F. Thompson, Sydney Ch’ng
20217
12
Reliable and Reproducible Murine Models for Commonly Used Abdominal Plastic Surgical Flaps
Journal of Reconstructive Microsurgery ·Jonathan Cubitt, Thomas E. Pennington, Chuanmin Wang, Richard D. Allen, Alex Bishop, Alexandra F. Sharland
20126
13
Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies
European Journal of Cancer ·Sydney Ch’ng, Semra Uyulmaz, Matteo S. Carlino, Thomas E. Pennington, Kerwin F. Shannon, Michael Rtshiladze, Jonathan R. Stretch, Omgo E. Nieweg, Alexander H. R. Varey, Edward Hsiao, Rony Kapoor, Inês Pires da Silva, Serigne Lo, Andrew J. Spillane, Richard A. Scolyer, Georgina V. Long, Angela Hong, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies
20215
14
Sonographic Volumetric Assessment Is a More Accurate Measure Than Maximum Diameter Alone in Papillary Thyroid Cancer
Journal of the Endocrine Society ·Thomas E. Pennington, May Myo Thwin, Mark Sywak, Leigh Delbridge, Stan B. Sidhu
20185
15
Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients
European Journal of Cancer ·Mary‐Ann El Sharouni, Richard A. Scolyer, Carla H. van Gils, Sydney Ch’ng, Omgo E. Nieweg, Thomas E. Pennington, Robyn P.M. Saw, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, Arjen J. Witkamp, V. Sigurdsson, John F. Thompson, P. J. van Diest, Serigne Lo
20225
16
Cervicothoracic Intradural Spinal Lipoma Without Dyraphism Diagnosed Postpartum
Military Medicine ·Nicholas Teneyuque, Kathy B. Porter, Thomas E. Pennington
20154
17
Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study
BMJ Open ·Kathy Dempsey, Robyn P.M. Saw, Iris Bartula, Serigne Lo, Craig Lawn, Thomas E. Pennington, Andrew J. Spillane, Frances Boyle, Skye Dong, Mbathio Dieng, Donna Milne, Linda Seaman, Dina Saks, Julia Lai‐Kwon, Jake Thompson, Rachael L. Morton
20223
18
1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial
Annals of Oncology ·N.M.J. Van Den Heuvel, Irene L. M. Reijers, Judith M. Versluis, Elisa A. Rozeman, Katarzyna Jóźwiak, K.H. Blommers, Robyn P.M. Saw, Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, Astrid A.M. van der Veldt, Geke A.P. Hospers, Andrew J. Spillane, Thomas E. Pennington, Michel W.J.M. Wouters, Alexander M. Menzies, Alexander C. J. van Akkooi, Lonneke V. van de Poll‐Franse, Georgina V. Long, Christian U. Blank, Annelies H. Boekhout
20203
19
1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Annals of Oncology ·Irene L. M. Reijers, Petros Dimitriadis, Alexander M. Menzies, Ellen Kapiteijn, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, Geke A.P. Hospers, Winan J. van Houdt, Robyn P.M. Saw, Annegien Broeks, Sten Cornelissen, Lindsay G. Grijpink-Ongering, Thomas E. Pennington, Andrew J. Colebatch, B. van de Wiel, Richard A. Scolyer, Alexander C. J. van Akkooi, Georgina V. Long, Christian U. Blank
20232
20
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
Annals of Surgical Oncology ·Alec A. Winder, Zoe Boyer, Sydney Ch’ng, Jonathan R. Stretch, Robyn P.M. Saw, Kerwin F. Shannon, Thomas E. Pennington, Omgo E. Nieweg, Alexander H. R. Varey, Richard A. Scolyer, John F. Thompson, Anne Ε. Cust, Serigne Lo, Andrew J. Spillane, Andrea L. Smith
20242

About Thomas E. Pennington

Thomas E. Pennington is a scholar working on Oncology, Molecular Biology, Immunology, Surgery and Epidemiology, having authored 42 papers that have together received 287 indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (29 papers), CAR-T cell therapy research (12 papers), Melanoma and MAPK Pathways (12 papers), Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (4 papers), Cell Image Analysis Techniques (2 papers), Nonmelanoma Skin Cancer Studies (2 papers) and Metastasis and carcinoma case studies (1 paper). The work is most often cited by research in Oncology (174 citations), Nephrology (22 citations), Immunology (59 citations), Organic Chemistry (43 citations) and Biophysics (6 citations). Thomas E. Pennington has collaborated with scholars based in Australia, Netherlands and United Kingdom. Frequent co-authors include Craig A. Hutton, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, Andrew J. Spillane, Robyn P.M. Saw, Kerwin F. Shannon, Maria Gonzalez, Serigne Lo and Karijn P.M. Suijkerbuijk. Their work appears in journals such as Journal of Clinical Oncology, Annals of Surgical Oncology, Annals of Oncology, European Journal of Cancer and European Journal of Surgical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feifei GuBreakdown of academic impact, for papers by Monique D. AppelmanBreakdown of academic impact, for papers by Ping AiBreakdown of academic impact, for papers by Cristina ValeroBreakdown of academic impact, for papers by Huixiong XuBreakdown of academic impact, for papers by Junqing GanBreakdown of academic impact, for papers by Bojan StojanovićBreakdown of academic impact, for papers by Qinglong KongBreakdown of academic impact, for papers by Chengfeng Wang